Like semaglutide, the new drug known as ecnoglutide is glucagon-like peptide-1 receptor agonist. In simple terms, they both ...

The researchers matched empagliflozin-treated patients to either semaglutide- or dulaglutide-treated patients using propensity score (PS) methods. In the primary trial analysis, 7,899 patients ...

The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

The association between GLP-1 RAs and the risk for NAION was assessed for the drug class as a whole and for each individual medication (dulaglutide, semaglutide, liraglutide, and exenatide). TAKEAWAY: ...

These drugs are the GLP1 receptor agonists like Exenatide, Liraglutde, Dulaglutide, Semaglutide and the dual GLP/ GIP Analogue Tirzepatide.

From a baseline HbA1c of 8.0%, the proportion of people achieving the American Diabetes Association target of HbA1c below 7.0% was statistically significantly greater with 14 mg oral semaglutide ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION).

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs (hazard ratios, 1.39 and 1.25 for semaglutide and liraglutide, respectively ...